search button

Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma

  • Authors:
    • Leonardo Gomes da Fonseca
    • Romualdo Barroso‑Sousa
    • Afonso da Silva Alves Bento
    • Bruna Paccola Blanco
    • Gabriel Luis Valente
    • Tulio Eduardo Flesch Pfiffer
    • Paulo Marcelo Hoff
    • Jorge Sabbaga

  • View Affiliations

  • Published online on: April 2, 2015     https://doi.org/10.3892/mco.2015.536
  • Pages: 793-796
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sorafenib demonstrated a survival benefit in the treatment of advanced hepatocellular carcinoma (HCC) in phase III trials. However, almost all the patients included in those trials exhibited well‑preserved liver function (Child‑Pugh A). The aim of this study was to describe our experience with sorafenib in Child‑Pugh B HCC patients. A database of patients with advanced HCC treated with sorafenib was retrospectively evaluated. The median overall survival of Child‑Pugh B patients (n=20) was 2.53 months [95% confidence interval (CI): 0.33‑5.92 months] and of Child‑Pugh A patients (n=100) 9.71 months (95% CI: 6.22‑13.04). Child‑Pugh B patients had a significantly poorer survival compared to Child‑Pugh A patients (P=0.002). The toxicities were similar between the two groups. Metastasis, vascular invasion and α‑fetoprotein level >1,030 ng/ml were not associated with survival among Child‑Pugh B patients (P=0.281, 0.189 and 0.996, respectively). Although the survival outcomes were worse in Child‑Pugh B patients treated with sorafenib, the toxicity profile was manageable. Therefore, there remains the question of whether to treat this subgroup of patients and more data are required to define the role of sorafenib in the context of liver dysfunction.
View Figures
View References

Related Articles

Journal Cover

July-2015
Volume 3 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
da Fonseca LG, Barroso‑Sousa R, Bento Ad, Blanco BP, Valente GL, Pfiffer TE, Hoff PM and Sabbaga J: Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 3: 793-796, 2015
APA
da Fonseca, L.G., Barroso‑Sousa, R., Bento, A.d., Blanco, B.P., Valente, G.L., Pfiffer, T.E. ... Sabbaga, J. (2015). Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Molecular and Clinical Oncology, 3, 793-796. https://doi.org/10.3892/mco.2015.536
MLA
da Fonseca, L. G., Barroso‑Sousa, R., Bento, A. d., Blanco, B. P., Valente, G. L., Pfiffer, T. E., Hoff, P. M., Sabbaga, J."Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma". Molecular and Clinical Oncology 3.4 (2015): 793-796.
Chicago
da Fonseca, L. G., Barroso‑Sousa, R., Bento, A. d., Blanco, B. P., Valente, G. L., Pfiffer, T. E., Hoff, P. M., Sabbaga, J."Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma". Molecular and Clinical Oncology 3, no. 4 (2015): 793-796. https://doi.org/10.3892/mco.2015.536